Target Price | $6.50 |
Price | $4.89 |
Potential |
32.92%
register free of charge
|
Number of Estimates | 4 |
4 Analysts have issued a price target bluebird bio, Inc. 2026 .
The average bluebird bio, Inc. target price is $6.50.
This is
32.92%
register free of charge
$8.00
63.60%
register free of charge
$5.00
2.25%
register free of charge
|
|
A rating was issued by 5 analysts: 1 Analysts recommend bluebird bio, Inc. to buy, 4 to hold and 0 to sell. | |
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
Analyst Estimates: Analysts believe that the bluebird bio, Inc. stock has an average upside potential 2026 of
32.92%
register free of charge
|
Dec '24 |
2025 Estimates |
|
---|---|---|
Revenue Million $ | 83.81 | 271.62 |
184.10% | 224.09% | |
EBITDA Margin | -246.34% | -35.24% |
76.46% | 85.69% | |
Net Margin | -288.38% | -28.24% |
77.34% | 90.21% |
6 Analysts have issued a sales forecast bluebird bio, Inc. 2025 . The average bluebird bio, Inc. sales estimate is
This results in the following potential growth metrics:
3 Analysts have issued an bluebird bio, Inc. EBITDA forecast 2025. The average bluebird bio, Inc. EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
7 bluebird bio, Inc. Analysts have issued a net profit forecast 2025. The average bluebird bio, Inc. net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Dec '24 |
2025 Estimates |
|
---|---|---|
Earnings Per Share $ | -24.84 | -7.88 |
35.63% | 68.28% | |
P/E | negative | |
EV/Sales | 1.25 |
7 Analysts have issued a bluebird bio, Inc. forecast for earnings per share. The average bluebird bio, Inc. EPS is
This results in the following potential growth metrics and future valuations:
bluebird bio, Inc....
Analyst | Rating | Action | Date |
---|---|---|---|
Barclays |
Locked
➜
Locked
|
Locked | Mar 31 2025 |
JP Morgan |
Locked
➜
Locked
|
Locked | Feb 24 2025 |
Wells Fargo |
Locked
➜
Locked
|
Locked | Feb 24 2025 |
Barclays |
Locked
➜
Locked
|
Locked | Dec 31 2024 |
B of A Securities |
Locked
➜
Locked
|
Locked | Nov 15 2024 |
Barclays |
Locked
➜
Locked
|
Locked | Nov 15 2024 |
RBC Capital |
Locked
➜
Locked
|
Locked | Nov 15 2024 |
Analyst Rating | Date |
---|---|
Locked
Barclays:
Locked
➜
Locked
|
Mar 31 2025 |
Locked
JP Morgan:
Locked
➜
Locked
|
Feb 24 2025 |
Locked
Wells Fargo:
Locked
➜
Locked
|
Feb 24 2025 |
Locked
Barclays:
Locked
➜
Locked
|
Dec 31 2024 |
Locked
B of A Securities:
Locked
➜
Locked
|
Nov 15 2024 |
Locked
Barclays:
Locked
➜
Locked
|
Nov 15 2024 |
Locked
RBC Capital:
Locked
➜
Locked
|
Nov 15 2024 |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.